Adjunctive Ivermectin Mass Drug Administration for Malaria Control
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive
benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to
dihydroartemisinin-piperaquine (DP) MDA for malaria control in a moderate to low
malaria-endemic setting as an adjunctive strategy to existing programmatic malaria control
measures. The regime of DP and IVM will target both human reservoirs of Plasmodium falciparum
and the Anopheles gambiae vector respectively, with the aim of interrupting transmission. The
trial will be conducted on the Bijagos Archipelago, where islands (clusters) will be
randomised to receive seasonal DP and IVM or DP and Placebo MDA. The primary outcome will be
the prevalence of infection with Plasmodium falciparum in all age groups detected by nucleic
acid amplification testing during the peak malaria transmission season after two years of
intervention.
Phase:
Phase 3
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
Bandim Health Project Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau Medical Research Council Unit, The Gambia Ministerio de Saude Publica, Guinee-Bissau